Day One Bio Day One Bio

May 2023

Phase 1 study of the pan RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma

May 2023

Chart audit in pediatric low-grade glioma: molecular testing and treatment patterns

May 2023

pLGG disease burden and healthcare utilization: linked claims and EHR data study

April 2023

Clinical activity of the type II pan-RAF inhibitor tovorafenib in BRAF-fusion melanoma

November 2022

FIREFLY-1 (PNOC026): Phase 2 study of pan-RAF inhibitor tovorafenib in pediatric and young adult patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors

November 2022

LOGGIC/FIREFLY-2: A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric patients with newly diagnosed low-grade glioma harboring an activating RAF alteration

June 2022

FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors

November 2021

Activity of pan-RAF inhibitor DAY101 in a pediatric patient with a recurrent spindle cell sarcoma harboring a novel SNX8-BRAF gene fusion

You are now leaving the Day One Biopharmaceuticals Corporate Website

You will now be redirected to the requested website. Please confirm that you want to proceed.